US3816423A - 2-aryl-4-amino-5-cyano pyrimidine derivatives - Google Patents
2-aryl-4-amino-5-cyano pyrimidine derivatives Download PDFInfo
- Publication number
- US3816423A US3816423A US00285153A US28515372A US3816423A US 3816423 A US3816423 A US 3816423A US 00285153 A US00285153 A US 00285153A US 28515372 A US28515372 A US 28515372A US 3816423 A US3816423 A US 3816423A
- Authority
- US
- United States
- Prior art keywords
- group
- radicals
- phenyl
- aryl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 239000002253 acid Substances 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- -1 1H-TETRAZOL-5-YL Chemical class 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 239000003874 central nervous system depressant Substances 0.000 abstract description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 150000005696 4-halopyrimidines Chemical class 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- VVAKEQGKZNKUSU-UHFFFAOYSA-N 2,3-dimethylaniline Chemical compound CC1=CC=CC(N)=C1C VVAKEQGKZNKUSU-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- YBEJLHAOCDKZIF-UHFFFAOYSA-N 4-chloro-6-methyl-2-phenylpyrimidine-5-carbonitrile Chemical compound ClC1=C(C#N)C(C)=NC(C=2C=CC=CC=2)=N1 YBEJLHAOCDKZIF-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical class [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Definitions
- pharmaceutically acceptable acid addition salts thereof possess central nervous system depressant and anti-inflammatory properties when administered to warm blooded animals.
- R, R and R are independently selected from the group consisting of H and lower alkyl radicals
- R and R are independently selected from the group consisting of H, lower alkyl and lower perfluoroalkyl radicals,
- X is a member selected from the group consisting of CN and N-N ll N-N H radicals, and
- the compounds of this invention are prepared by reaction of an appropriately substituted benzamidine hydrochloride NH @ii-Nm-Hm RI with a compound of the structure:
- R N H @h NE A in which the groups R, R and R are independently selected from the group consisting of --H and lower alkyl radicals;
- R and R are independently selected from the group consisting of H, lower alkyl and lower perfluoroalkyl radicals,
- An alternative route to the intermediate 4-halopyrimidines, and the preferred synthesis of a 5-cyano4-halo derivative involves the conversion of a 5-carboalkoxy-4- hydroxy-Z-aryl-pyrimidine to the 5-carbamyl derivative by treatment with concentrated ammonium hydroxide in a sealed steel bomb at steam bath temperature. The resulting amide is converted to the 5-cyano4-halo product in high yield by refluxing it with a large excess of -POCl (J. Heterocycl. Chem., vol. 8, pp. 715-719 (1971)).
- the pharmaceutically acceptable acid addition salts are prepared by conventional processing of the base with those non-toxic acids, organic or inorganic, known to be acceptable in formulation of compounds for oral and parenteral administration, such as hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, nitric, ptoluene sulfonic, acetic, citric, maleic, succinic and the like.
- lower alkyl is used throughout this specification to define straight and branched chain monovalent hydrocarbon radicals containing from one to 7 carbon atoms such as methyl, ethyl, i-propyl, n-priopyl, n-butyl, n-hexyl, and the like.
- Both the 5-(IE-tetrazol-S-yl)pyrimidine derivative of this invention and the 5-cyano-4-m-trifluoromethylanilinopyrimidine precursor exhibited central nervous system depressant activity at dosage levels as low as 40 milligram per kilogram body weight when administered intraperitoneally to three mice at each of the dosage levels 400, 127, 40 and 12.7 milligrams per kilogram host body weight.
- the activity was observed by watching the test mice for a minimum of two hours during which time any signs of general stimulation (i.e. increased spontaneous motor activity, hyperactivity on tactile stimulation, twitching), general depression (i.e. decreased spontaneous motor activity, decreased respiration and autonomic activity (i.e. miosis, mydriasis, diarrhea) were noted.
- the 5-cyano- 4-m-t1ifluoromethylanilino-pyrimidine derivative demonstrated central nervous system activity as a depressant with marked decrease in motor activity, decreased respiration and ataxia, while the S-(IE-tetrazol-S-yl) pyrimidine derivative exhibited decreased respiration and motor activity without indication of ataxis.
- depressant activity is induced at dosage levels well below that found to be excessive.
- a 43 percent inhibition of experimentally induced edema in the hind paw of male rats weighing from 120-160 grams was observed.
- -In practice from 1.0 to 100 milligrams of the compound being tested per kilogram body weight of the rat was administered orally to six rats with a six rat control being administered aqueous vehicle with no active compound.
- edema was induced by injection of 0.05 milliliters of 1 percent carrageenin solution in saline into the subplanar tissue of the rats right hind paw.
- the paw volume was immediately volumetrically determined with a plethysmograph and again 3 hours later.
- the mean volume swelling for the control group was determined and compared to the test group. Swelling inhibition of 23 percent or more is considered to be indicative of an active compound.
- the compound, 2-phenyl-5-1g-tetrazol-5-yl)-4-(a,a,! trifluoro-m-toluidino)pyrimidine displayed moderate anti-inflammatory activity (more than 20 percent change at one millimolar concentration) when examined in vitro for albumin denaturation inhibition in a manner similar to that of Mizushima, Arch. int. Pharmacodyn, 149, 1-7 (1964); acceleration of a disulfide-sulfhydryl interchange in serum albumin when examined in a manner similar to that of Gerber et al., Biochem, Pharmacol, 16, 115-123 (1967); and inhibition of aldehyde binding to albumin when examined in a manner similar to that of Skidmore et al., J. Pharm. Pharmacol. 17, 671-673 (1965).
- the compounds of this invention serve as intraperitoneally administerable central nervous system de- 4 pressants and as anti-inflammatory agents via either intraperitoneal or oral administration.
- the proportion of which is determined by the chosen route in which of administration and standard pharmaceutical practice.
- they may be administered orally in tablet or capsule form with conventional flavors, diluents, lubricants, disintegrators or binding agents as may be re- 5 quired.
- They may be administered orally in the form of a solution or they may be injected parenterally.
- parenteral administration they may be used in the form of a sterile solution containing other solutes, for example,
- R, R and R are members independently selected from the group consisting of H and alkyl of 1 to 7 carbon atoms,
- R and R are members independently selected from the group consisting of --H, alkyl of 1 to 7 carbon atoms and perfluoroalkyl of 1 to 7 carbon atoms,
- X is a member selected from the group consisting of enough saline or glucose to make the solution isotonic. 10
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOUNDS OF THE FORMULA:
2-(R1-PHENYL),4-R2,5-X,6-((R3,R4-PHENYL)-N(-R)-)PYRIMIDINE
IN WHICH R, R1 AND R2 ARE INDEPENDENTLY SELECTED FROM THE GROUP, CONSISTING OF -H AND LOWER ALKYL RADICALS, R3 AND R4 ARE INDEPENDENTLY SELECTED FROM THE GROUP CONSISTING OF -H, LOWER ALKYL AND LOWER PERFLUOROALKYL RADICALS, X IS A MEMBER SELECTED FROM THE GROUP CONSISTING OF -CN AND
1H-TETRAZOL-5-YL
RADICALS, AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, POSSESS CENTRAL NERVOUS SYSTEM DEPRESSANT AND ANTI-INFLAMMATORY PROPERTIES WHEN ADMINISTERED TO WARM BLOODED ANIMALS.
2-(R1-PHENYL),4-R2,5-X,6-((R3,R4-PHENYL)-N(-R)-)PYRIMIDINE
IN WHICH R, R1 AND R2 ARE INDEPENDENTLY SELECTED FROM THE GROUP, CONSISTING OF -H AND LOWER ALKYL RADICALS, R3 AND R4 ARE INDEPENDENTLY SELECTED FROM THE GROUP CONSISTING OF -H, LOWER ALKYL AND LOWER PERFLUOROALKYL RADICALS, X IS A MEMBER SELECTED FROM THE GROUP CONSISTING OF -CN AND
1H-TETRAZOL-5-YL
RADICALS, AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, POSSESS CENTRAL NERVOUS SYSTEM DEPRESSANT AND ANTI-INFLAMMATORY PROPERTIES WHEN ADMINISTERED TO WARM BLOODED ANIMALS.
Description
United States Patent 3,816,423 Patented June 11, 1974 3,816,423 2-ARYL-4-AMlN0-S-CYANO PYRIMIDINE DERIVATIVES Dong H. Kim, Wayne, and Arthur A. Sanfilli, Havertown, Pa., assignors to, American Home Products Corporation, New York, N.Y. No Drawing. Filed Aug. 31, 1972, Ser. No. 285,153 Int. Cl. C07d 51/42 US. Cl. 260-256.4 N
3 Claims ABSTRACT OF THE DISCLOSURE Compounds of the formula:
l NR radicals, and
pharmaceutically acceptable acid addition salts thereof, possess central nervous system depressant and anti-inflammatory properties when administered to warm blooded animals.
BRIEF DESCRIPTION OF THE INVENTION In accordance with this invention there is provided a new means for inducing central nervous system depressant activity and anti-inflammatory activity in warm blooded animals by administering to the animals an effective dose of one or more members of the compound aspect of this invention as depicted by the formula:
in which R, R and R are independently selected from the group consisting of H and lower alkyl radicals,
R and R are independently selected from the group consisting of H, lower alkyl and lower perfluoroalkyl radicals,
X is a member selected from the group consisting of CN and N-N ll N-N H radicals, and
pharmaceutically acceptable acid addition salts thereof.
The compounds of this invention are prepared by reaction of an appropriately substituted benzamidine hydrochloride NH @ii-Nm-Hm RI with a compound of the structure:
CN mo -0:0
r coiEt to afford the 2-aryl pyrimidine heterocycle @kN 0H which is readily converted to the 4-halo substituted derivative by reaction with a reagent such as POCl PO1 PCI;,,
and the like. The 4-halo pyrimidine derivative reacts smoothly with amines of the formula:
and subsequently with an azide, such as sodium azide, to produce the lg-tetrazole of the structural formula:
to yield IR. N-N
R N H @h NE A in which the groups R, R and R are independently selected from the group consisting of --H and lower alkyl radicals;
R and R are independently selected from the group consisting of H, lower alkyl and lower perfluoroalkyl radicals,
An alternative route to the intermediate 4-halopyrimidines, and the preferred synthesis of a 5-cyano4-halo derivative, involves the conversion of a 5-carboalkoxy-4- hydroxy-Z-aryl-pyrimidine to the 5-carbamyl derivative by treatment with concentrated ammonium hydroxide in a sealed steel bomb at steam bath temperature. The resulting amide is converted to the 5-cyano4-halo product in high yield by refluxing it with a large excess of -POCl (J. Heterocycl. Chem., vol. 8, pp. 715-719 (1971)).
The pharmaceutically acceptable acid addition salts are prepared by conventional processing of the base with those non-toxic acids, organic or inorganic, known to be acceptable in formulation of compounds for oral and parenteral administration, such as hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, nitric, ptoluene sulfonic, acetic, citric, maleic, succinic and the like.
The term lower alkyl is used throughout this specification to define straight and branched chain monovalent hydrocarbon radicals containing from one to 7 carbon atoms such as methyl, ethyl, i-propyl, n-priopyl, n-butyl, n-hexyl, and the like.
Both the 5-(IE-tetrazol-S-yl)pyrimidine derivative of this invention and the 5-cyano-4-m-trifluoromethylanilinopyrimidine precursor exhibited central nervous system depressant activity at dosage levels as low as 40 milligram per kilogram body weight when administered intraperitoneally to three mice at each of the dosage levels 400, 127, 40 and 12.7 milligrams per kilogram host body weight. The activity was observed by watching the test mice for a minimum of two hours during which time any signs of general stimulation (i.e. increased spontaneous motor activity, hyperactivity on tactile stimulation, twitching), general depression (i.e. decreased spontaneous motor activity, decreased respiration and autonomic activity (i.e. miosis, mydriasis, diarrhea) were noted. The 5-cyano- 4-m-t1ifluoromethylanilino-pyrimidine derivative demonstrated central nervous system activity as a depressant with marked decrease in motor activity, decreased respiration and ataxia, while the S-(IE-tetrazol-S-yl) pyrimidine derivative exhibited decreased respiration and motor activity without indication of ataxis. Thus, depressant activity is induced at dosage levels well below that found to be excessive.
The compound, 2-phenyl-4-(a,a,w-trifluorom-toluidino)-5-pyrimidinecarbonitrile, exhibits anti-inflammatory activity evidenced by diminished swelling of carrageenin induced edema. Thus, a 43 percent inhibition of experimentally induced edema in the hind paw of male rats weighing from 120-160 grams was observed. -In practice, from 1.0 to 100 milligrams of the compound being tested per kilogram body weight of the rat was administered orally to six rats with a six rat control being administered aqueous vehicle with no active compound. Sixty minutes after drug administration, edema was induced by injection of 0.05 milliliters of 1 percent carrageenin solution in saline into the subplanar tissue of the rats right hind paw. The paw volume was immediately volumetrically determined with a plethysmograph and again 3 hours later. The mean volume swelling for the control group was determined and compared to the test group. Swelling inhibition of 23 percent or more is considered to be indicative of an active compound.
The compound, 2-phenyl-5-1g-tetrazol-5-yl)-4-(a,a,! trifluoro-m-toluidino)pyrimidine, displayed moderate anti-inflammatory activity (more than 20 percent change at one millimolar concentration) when examined in vitro for albumin denaturation inhibition in a manner similar to that of Mizushima, Arch. int. Pharmacodyn, 149, 1-7 (1964); acceleration of a disulfide-sulfhydryl interchange in serum albumin when examined in a manner similar to that of Gerber et al., Biochem, Pharmacol, 16, 115-123 (1967); and inhibition of aldehyde binding to albumin when examined in a manner similar to that of Skidmore et al., J. Pharm. Pharmacol. 17, 671-673 (1965).
Thus, the compounds of this invention serve as intraperitoneally administerable central nervous system de- 4 pressants and as anti-inflammatory agents via either intraperitoneal or oral administration.
DETAILED DESCRIPTION OF THE INVENTION The following preparative procedures for producing the compounds of this invention are presented for purpose of illustration and are not to be construed as the limiting factors on the proper scope of the disclosed invention. It is recognized that those of average skill in the art, when apprized of the invention herein disclosed will contemplate and be placed in possession of applicants contribution to the extent of its true scope.
EXAMPLE I 2-Phenyl-4-(a,a,a-trifiuoro-m-toluidino)- 5 -pyrimidinecarbonitrile A mixture of 4-chloro-2phenyl-S-pyrimidinecarbonitrile (5.0 grams), a,a,a-trifluoro-m-toluidine (15 milliliters), and ethanol (20 milliliters) was heated under reflux for 1 hour. Chilling of the reaction mixture in ice caused separation of a precipitate which was collected on a filter. The product was recrystallized from ethanol, yield 6.5 grams, M.P. -197 C.
Elemental analysis Calcd for C H F N C, 63.53; H, 3.26; N, 16.46. Found: C, 63.36; H, 3.22; N, 16.71.
EXAMPLE II 2- (p-Tolyl -4- 2,3 -dimethylanilino S-pyrimidinecarbonitrile Reflux a mixture of 4-ch1oro-2-(p-tolyl)-5-pyrimidinecarbonitrile with an equimolar amount of 2,3-dimethylaniline and ethanol for about one hour. Cool the resulting reaction mixture with ice water to obtain the title compound.
EXAMPLE III 6-Methyl-2-phenyl-4-(c n,a-trifluordm-toluidino)- 5-pyrimidinecarbonitrile Reflux a mixture of 4-chloro-6-methyl-2-phenyl-5-pyrimidinecarbonitrile with a slight stoichiometric excess of a,oz,oL-trifiuOIO-m-IO1l1idine and ethanol for about one hour. Quench the product in ice water and recrystallize the product from ethanol to obtain the title compound.
EXAMPLE IV 2-Phenyl-5-(1g-tetrazol-5-yD-4-(u,a,atrifluoro-m-toluidino -pyrimidine Elemental analysis Calcd for C H F N C, 56.40; H, 3.16; N, 25.58. Found: C, 56.22; H, 2.93; N, 25.61.
Similarly, the products of Examples II and III react with sodium azide to produce the corresponding 5-(1H- tetrazol-S-yl) substituted compounds.
When the compounds of the invention are employed as described above they may be administered alone or in combination with pharmacologically acceptable carriers,
the proportion of which is determined by the chosen route in which of administration and standard pharmaceutical practice. For example, they may be administered orally in tablet or capsule form with conventional flavors, diluents, lubricants, disintegrators or binding agents as may be re- 5 quired. They may be administered orally in the form of a solution or they may be injected parenterally. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example,
R, R and R are members independently selected from the group consisting of H and alkyl of 1 to 7 carbon atoms,
R and R are members independently selected from the group consisting of --H, alkyl of 1 to 7 carbon atoms and perfluoroalkyl of 1 to 7 carbon atoms,
X is a member selected from the group consisting of enough saline or glucose to make the solution isotonic. 10
It is most advantageous to provide the compound as a and dry powder in a suitable container so that it may be ad- N-N mixed with a suitable aqueous vehicle prior to adminis- H nati and pharmaceutically acceptable acid addition salts there- What is claimed is: 15 1. A compound of the formula: 2. The compound which is 2-phenyl-4-(u,u,u-tr1fluorom-toluidino)-5-pyrimidinecarbonitrile.
3. The compound which is Z-phenyI-S-(IE-tetrazol- S-yl)-4-(u,a,a-trifluoro-m-toluidine)pyrimidine.
x References Cited m N I UNITED STATES PATENTS m NR 3,563,984 2/1971 Kim et al. 260-244 25 DONALD G. DAUS, Primary Examiner R. v. RUSH, Assistant Examiner R US. Cl. X.R.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00285153A US3816423A (en) | 1972-08-31 | 1972-08-31 | 2-aryl-4-amino-5-cyano pyrimidine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00285153A US3816423A (en) | 1972-08-31 | 1972-08-31 | 2-aryl-4-amino-5-cyano pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3816423A true US3816423A (en) | 1974-06-11 |
Family
ID=23092971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US00285153A Expired - Lifetime US3816423A (en) | 1972-08-31 | 1972-08-31 | 2-aryl-4-amino-5-cyano pyrimidine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3816423A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4025514A (en) * | 1973-09-20 | 1977-05-24 | Delalande S.A. | Arylamino pyrimidinic derivatives |
| EP1549316A4 (en) * | 2002-09-10 | 2008-04-09 | Scios Inc | INHIBITORS OF TFGbeta |
-
1972
- 1972-08-31 US US00285153A patent/US3816423A/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4025514A (en) * | 1973-09-20 | 1977-05-24 | Delalande S.A. | Arylamino pyrimidinic derivatives |
| EP1549316A4 (en) * | 2002-09-10 | 2008-04-09 | Scios Inc | INHIBITORS OF TFGbeta |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3696197A (en) | Pharmaceutical compositions containing homopyrimidazole derivatives | |
| Ergenç et al. | Synthesis and hypnotic activity of new 4‐thiazolidinone and 2‐thioxo‐4, 5‐imidazolidinedione derivatives | |
| US3780040A (en) | 2-substituted-3,4-dihydroquinazolines | |
| SU843746A3 (en) | Method of preparing aminothiazoles or their acid-additive salts | |
| US3910913A (en) | 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives | |
| JPH0559118B2 (en) | ||
| US3631043A (en) | Di- and triphenylpropyl piperazine compounds | |
| FI57408C (en) | FREQUENCY REFRIGERATION OF ANTI-ALLERGY 3- (TETRAZOLE-5-YL) CHROMONER | |
| EP1109814B1 (en) | 5-heterocyclyl pyrazolo 4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction | |
| JPH0226629B2 (en) | ||
| US3816423A (en) | 2-aryl-4-amino-5-cyano pyrimidine derivatives | |
| JP2002544258A (en) | Ion channel regulator | |
| US6800623B2 (en) | Method of treating schizophrenia | |
| US3631036A (en) | 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds | |
| EP0290558B1 (en) | Antifolate agents | |
| US3860596A (en) | 2-aryl-4-substituted-amino-5-pyrimidyl derivatives | |
| GB2077725A (en) | Adenosine derivatives production thereof and compositions containing them | |
| US2845425A (en) | Substituted aminopyrimidines | |
| US4065451A (en) | 1,3-Dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts | |
| US3836658A (en) | Tri-substituted imidazoles in the treatment of gout | |
| US3725405A (en) | 2,4,7-TRISUBSTITUTED-{8 PYRIDO 2,3-d{9 PYRIMIDINE-6-CARBOXAMIDES | |
| AU708253B2 (en) | Phosphinic acid derivatives, their preparation and their use | |
| US3694450A (en) | 2-substituted-4,5,6,7-tetrahydrobenzothiazole-4-carboxylic acids and their alkyl esters | |
| US3598824A (en) | 7h-pyrrolo 2,3-d pyrimidine-5-acetimidates | |
| JPS58146573A (en) | Anti-depressive novel 2-piperazinyl-4- phenylquinazoline derivative, manufacture and medicine |